Completed Projects

HOME > R&D Pipeline > Current status > Completed Projects

KDDF-201406-06 Validation of synthetic small-molecule lead compound to develop anti-cancer drug for T-cell lymphoma and finding its mechanism of action(Oncology, Chemical) [10.01.2014]

PRINT

Development and Market Objectives

Validation of synthetic small-molecule lead compound to develop anti-cancer drug for T-cell lymphoma and finding its mechanism of action

Unmet Medical Need & Target Patients

Patients with peripheral T-cell lymphomas have often been relapsed or refractory about conventional therapy. Since their 5-year survival rate is below 30%, effective first-line treatments are needed.  
 Vincristine, a well-known microtubule inhibitor, is widely used but its effective capacity is restricted due to severe peripheral neurotoxicity. The development of new therapeutic drug targeting microtubule with low peripheral neurotoxicity and a strong cytotoxic effect toward T-cell lymphoma is urgently needed.
                                                   
The development of new drug with minimal side effects and that can be used in combination with other therapies is needed.

Status

Efficacy against T-cell lymphoma has been confirmed with the lead compound that induces microtubule depolymerization.
We are currently analyzing the effectiveness of the lead compound, together with multilateral evaluation of peripheral neurotoxicity and investigating the mechanism of action.

Intellectual Property

Domestic patent and PCT application have been completed

Competitive Advantages

- Can effectively eliminate T-cell lymphoma that exist within both lymphatic and non-lymphatic organs
- Has high drug selectivity for not only for T-cell lymphoma, but also tumor cells arising from other lymphocytes
- Has low peripheral neurotoxicity at effective concentrations
- Has strongly cytotoxic effects toward multidrug-resistant T-cell lymphoma
- Can be used in combination with other therapies
 

Indication

Lymphoma

Research Period

Sep, 2014 ~ Aug, 2015

Company

Inje University

Developmental Stage

Lead Generation

Additional Information

Contact Information

Contact
Address Company Name: Inje University
WebSite Homepage: http://www.inje.ac.kr Contact Person: Sungmin Lee
E-mail: 2sm1983@hanmail.net Contact: +82-51-890-6743

Related Projects

Related Project
list
Update to 2013 © KOREA DRUG DEVELOPMENT FUND. ALL RIGHTS RESERVED. QR Code